CZ20012032A3 - Nové způsoby léčby zhoubného bujení - Google Patents

Nové způsoby léčby zhoubného bujení

Info

Publication number
CZ20012032A3
CZ20012032A3 CZ20012032A CZ20012032A CZ20012032A3 CZ 20012032 A3 CZ20012032 A3 CZ 20012032A3 CZ 20012032 A CZ20012032 A CZ 20012032A CZ 20012032 A CZ20012032 A CZ 20012032A CZ 20012032 A3 CZ20012032 A3 CZ 20012032A3
Authority
CZ
Czechia
Prior art keywords
treatment methods
novel treatment
malignant proliferation
derivatives
cells
Prior art date
Application number
CZ20012032A
Other languages
English (en)
Other versions
CZ300499B6 (cs
Inventor
Angus George Dalgleish
Peter Michael Smith
Andrew Derek Sutton
Anthony Ian Walker
Original Assignee
Onyvax Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onyvax Limited filed Critical Onyvax Limited
Publication of CZ20012032A3 publication Critical patent/CZ20012032A3/cs
Publication of CZ300499B6 publication Critical patent/CZ300499B6/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/884—Vaccine for a specifically defined cancer prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CZ20012032A 1998-12-10 1999-12-09 Použití bunecných linií lidské prostaty k lécbe zhoubného bujení prostaty CZ300499B6 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9827104.2A GB9827104D0 (en) 1998-12-10 1998-12-10 New cancer treatments

Publications (2)

Publication Number Publication Date
CZ20012032A3 true CZ20012032A3 (cs) 2001-10-17
CZ300499B6 CZ300499B6 (cs) 2009-06-03

Family

ID=10843926

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ20012032A CZ300499B6 (cs) 1998-12-10 1999-12-09 Použití bunecných linií lidské prostaty k lécbe zhoubného bujení prostaty

Country Status (19)

Country Link
US (3) US6972128B1 (cs)
EP (1) EP1137422B1 (cs)
JP (2) JP4949554B2 (cs)
KR (1) KR20010090874A (cs)
AT (1) ATE304365T1 (cs)
AU (1) AU763485B2 (cs)
CA (1) CA2354045C (cs)
CZ (1) CZ300499B6 (cs)
DE (1) DE69927286T2 (cs)
ES (1) ES2249046T3 (cs)
GB (1) GB9827104D0 (cs)
HU (1) HUP0104568A3 (cs)
IL (2) IL143296A0 (cs)
MX (1) MXPA01005816A (cs)
NO (1) NO327044B1 (cs)
NZ (1) NZ512004A (cs)
PL (1) PL201016B1 (cs)
WO (1) WO2000033869A2 (cs)
ZA (1) ZA200104164B (cs)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9827104D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments
GB9827103D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments
AU4935700A (en) * 1999-05-21 2000-12-12 Onyvax Limited New vaccine formulations-3
DK1272617T3 (da) * 2000-04-01 2011-08-22 Onyvax Ltd Prostata cellelinier og deres anvendelse
US6667479B2 (en) * 2001-06-01 2003-12-23 Raytheon Company Advanced high speed, multi-level uncooled bolometer and method for fabricating same
US20050019336A1 (en) 2003-07-23 2005-01-27 Dalgleish Angus George Human prostate cell lines in cancer treatment
AU2004270113A1 (en) * 2003-08-26 2005-03-17 Becton, Dickinson And Company Methods for intradermal delivery of therapeutics agents
US9045556B2 (en) 2007-02-07 2015-06-02 Nec Corporation Therapeutic agent for cancer
EP2216041A4 (en) * 2007-11-20 2012-10-24 Nec Corp METHOD OF INDUCING A CYTOTOXIC T-CELL, CYTOTOXIC T-CELL INDUCTOR AND PHARMACEUTICAL COMPOSITION, AND VACCINE WITH THE INDUCTOR
AU2009200767A1 (en) * 2008-03-10 2009-09-24 Aristocrat Technologies Australia Pty Limited A gaming system and a method of gaming
US9974844B2 (en) * 2008-11-17 2018-05-22 The Regents Of The University Of Michigan Cancer vaccine compositions and methods of using the same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1216710B1 (en) * 1991-10-04 2006-04-05 Whitehead Institute For Biomedical Research Regulation of systemic immune responses utilizing cytokines and antigens
JPH05246889A (ja) * 1992-03-05 1993-09-24 Seitai Chiyousetsu Kenkyusho:Kk 制癌方法および制癌剤
WO1995029704A1 (en) * 1994-04-28 1995-11-09 Scott Freeman Cell lines obtained by in vivo migration and by fusion with autoimmune cells
JP3201610B2 (ja) * 1995-03-17 2001-08-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 腫瘍を処置する方法
US5788963A (en) * 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
WO1997024132A1 (en) * 1995-12-28 1997-07-10 The Johns Hopkins University School Of Medicine Allogeneic paracrine cytokine tumor vaccines
WO1997028255A1 (en) * 1996-02-02 1997-08-07 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Immortal human prostate epithelial cell lines and clones and their applications in the research and therapy of prostate cancer
GB9620350D0 (en) * 1996-09-30 1996-11-13 Maudsley David J Cancer vaccine
US6207805B1 (en) * 1997-07-18 2001-03-27 University Of Iowa Research Foundation Prostate cell surface antigen-specific antibodies
GB9827104D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments

Also Published As

Publication number Publication date
GB9827104D0 (en) 1999-02-03
EP1137422A2 (en) 2001-10-04
JP2012021028A (ja) 2012-02-02
CZ300499B6 (cs) 2009-06-03
KR20010090874A (ko) 2001-10-19
JP4949554B2 (ja) 2012-06-13
EP1137422B1 (en) 2005-09-14
CA2354045C (en) 2012-02-21
MXPA01005816A (es) 2002-03-27
US20120164099A1 (en) 2012-06-28
PL201016B1 (pl) 2009-02-27
ES2249046T3 (es) 2006-03-16
US20050249756A1 (en) 2005-11-10
US6972128B1 (en) 2005-12-06
AU1668300A (en) 2000-06-26
NZ512004A (en) 2003-08-29
NO327044B1 (no) 2009-04-06
PL348828A1 (en) 2002-06-17
HUP0104568A3 (en) 2004-05-28
IL143296A0 (en) 2002-04-21
NO20012634L (no) 2001-08-08
AU763485B2 (en) 2003-07-24
DE69927286T2 (de) 2006-06-29
HUP0104568A2 (hu) 2002-03-28
WO2000033869A3 (en) 2000-10-12
JP2002531520A (ja) 2002-09-24
NO20012634D0 (no) 2001-05-29
CA2354045A1 (en) 2000-06-15
WO2000033869A2 (en) 2000-06-15
US8034360B2 (en) 2011-10-11
ZA200104164B (en) 2002-01-24
ATE304365T1 (de) 2005-09-15
DE69927286D1 (de) 2005-10-20
IL143296A (en) 2006-06-11

Similar Documents

Publication Publication Date Title
GEP20094798B (en) (s,s)-reboxetine for treating chronic pain
MY155218A (en) Small molecules useful in the treatment of inflammatory disease
ES2191152T3 (es) Terapia combinada para el tratamiento de psicosis.
NO20021830L (no) Sammensetninger egnet til å forhindre og behandle forkjölelse og influensaliknende symptomer samt fremgangsmåter vedfremstilling derav
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
CZ20012032A3 (cs) Nové způsoby léčby zhoubného bujení
CA2253632A1 (en) Compositions and methods for treating cancers and pathogen infections using antigen-presenting cells loaded with rna
WO1992002240A3 (en) Novel methods and compositions for treatment of angiogenic diseases
MXPA05005107A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
AU2001235006A1 (en) Prophylactic and therapeutic monoclonal antibodies
IL131701A0 (en) Compositions for treating tumors containing shark cartilage extracts and anti-neoplastic agents
HUP0104688A3 (en) Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
MXPA01010982A (es) Uso de phyllanthus para la estimulacion dirigida al objetivo del sistema inmune.
IL153680A0 (en) Aplidine derivatives and methods for the preparation thereof
WO2002066044A3 (en) Method for dendritic cells based immunotherapy of tumors using combination therapy
IL117874A0 (en) Pharmaceutical compositions for inhibiting the growth of viruses and cancers
EP1159967A4 (en) TUMOR VACCINE
DE69938192D1 (en) Imidazonaphthyridine
MXPA03001643A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
SI1546182T1 (sl) Sestavki in postopki za diagnozo in zdravljenje tumorja
AU3439799A (en) Immunization against and treatment for infection by (h.pylori)
AU2002251754A1 (en) Therapeutic modulation of the tumor inflammatory response
PL357179A1 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
AU2821000A (en) Matrix protein compositions for induction of apoptosis
AU1128801A (en) Agents for treating human diseases, especially for treating tumors such as colonic cancers and melanomas or for regenerating tissue and promoting hair growth

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of fee

Effective date: 19991209